Shengyu Decoction and Lijin Manipulation for Knee OA: 3D Gait Analysis

Early Phase 1Enrolling By InvitationNCT06451783

Xuhui Central Hospital, Shanghai94 enrolled

Overview

Detailed Description Avoid duplicating information that will be entered or uploaded elsewhere in the record.

This study aims to explore the efficacy of the Shengyu Decoction combined with manual therapy for the treatment of knee osteoarthritis (OA) using a clinical randomized controlled trial design. Additionally, based on three-dimensional gait analysis technology, the investigators will delve into the biomechanical mechanisms underlying the onset of knee OA and elucidate the mechanism of action of the Shengyu Decoction combined with manual therapy. This will further validate the clinical superiority of the Shengyu Decoction combined with manual therapy in the treatment of knee OA, providing strong support for reducing pain and improving knee function in patients with knee OA.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Osteoarthritis of the Knee

Interventions

Traditional Chinese medicine combined with manipulation treatmentOTHER

The specific procedure involves administering the Shengyu Decoction, which consists of the following herbs: * Shu Di Huang 20 grams * Bai Shao 15 grams * Dang Gui 15 grams * Chuan Xiong 8 grams * Ren Shen 20 grams * Huang Qi 18 grams One dose is taken per day, and a course of treatment consists of five weeks. Add manipulation of massage： * Press and grasp the affected limb three times； * Five-finger five-acupoint pressing method； * Point pressing on Zusanli (ST36) and Sanyinjiao (SP6)； * grasp the interior method to treat the calf three times； ⑤ Apply rolling technique around the knee joint； ⑥ Knead and straighten the standing tendon (the lateral muscle of the calf)； ⑦ Six-finger six-acupoint pressing method； ⑧ Push and pull the patella to flex and extend the knee joint； ⑨ Knee joint reunion and smooth dispersion method.

Celecoxib capsuleDRUG

Oral Celecoxib Capsules, 200mg per dose, once daily after lunch.

Eligibility

Sex: ALLMin age: 45 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnostic criteria of Western medicine: Knee pain for at least 1 month, X-ray showing osteophyte formation, age ≥50 years, morning stiffness ≤30 min, and bone fricative sound. * TCM diagnostic criteria: Dull pain in the knee joint, flexion and extension limitations, pitching and side rotation unfavorability, slight activities slightly relieve pain, climate change aggravates symptoms, and repeated middle-aged and elderly patients, hidden onset, slow onset, slight local swelling of the knee joint, friction or clicking sound when moving, and severe cases may show muscle atrophy and joint deformity. * Radiographs showing joint space narrowing, bone hyperplasia, subchondral osteosclerosis, and osteophyte formation. * Patients who are between 45 and 85 years old. * Patients who can understand and provide informed consent. * Patients who are willing and able to undergo manual treatment for 1 course of treatment and cooperate with the doctor to complete the study. Exclusion Criteria: * Patients who do not meet the diagnostic criteria for knee osteoarthritis established by the rheumatology society. * Severe knee pain with surgical indications (or X-ray grading standards reached level 4). * Pregnant or planning to become pregnant. * Patients who have participated in or are participating in other clinical trials within the last 3 months. * Patients who have received or are receiving other treatment methods such as drugs that affect the evaluation of efficacy within the past 3 months. * Patients with fractures, dislocation, skin damage, and severe infectious skin diseases within three weeks. * Patients with severe primary diseases such as liver, kidney, hematopoietic system, endocrine system, cardiovascular and cerebrovascular, nervous system, tuberculosis, joint malformations, tumors, and psychiatric patients and postoperative patients. * Patients who are unable to accurately evaluate the effectiveness and safety of treatment due to their medical condition.

Locations (1)

Qiao Liang

Shanghai, China

Outcomes

Primary Outcomes

The western Ontario and McMaster universities osteoarthritis index

The WOMAC consists of a series of questions that capture the patient's perception of pain, stiffness, and physical function over the past week. It is scored on a numerical scale, with higher scores indicating greater impairment. The index is often used in clinical trials and epidemiological studies to measure changes in osteoarthritis symptoms and to assess the effectiveness of treatments.

Time frame: up to 13 weeks

Secondary Outcomes

Measurement of Gait Dynamics Parameters in Patients with Knee Osteoarthritis

Stride Length in meters

Time frame: up to 13 weeks

Measurement of Gait Dynamics Parameters in Patients with Knee Osteoarthritis

Walking Speed in meters per second

Time frame: up to 13 weeks

Gait Speed in meters per second

Gait Analysis

Time frame: up to 13 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.